Associated Papers
Resistance to targeted therapy in chronic myelogenous leukemia.
Hochhaus A et al.
Seminars in Hematology, 2007
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP et al.
Cancer Cell, 2002
Select a paper to view details